In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AcuFocus, Inc.

http://www.acufocus.com/

Latest From AcuFocus, Inc.

US Health And Wellness Executive Decisions: Herbalife, Bausch + Lomb, Cascadia Capital

Herbalife distributor leaves board to be strategy chief; Bausch + Lomb increases executive posts; and Cascadia Capital director’s focus includes sports nutrition.

Executive Changes OTC Drugs

Device/Diagnostics Quarterly Deal Statistics, Q3 2016

Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.

Market Intelligence Deals

The View Beyond LASIK: New Techs Further Propel Refractive Surgical Market

LASIK continues to hold a dominant share of the refractive surgical market but limitations in current technologies are stymying further growth. However, a tide of innovation refractive correction is coming in now, and over the next few years that will accelerate growth in this market and fully capitalize on this huge and yet undertapped opportunity known as presbyopia. This article discusses drivers and barriers in the refractive correction market and highlights three companies to look out for this space.

Ophthalmology Market Intelligence

James Mazzo To Head Carl Zeiss' Ophthalmic Biz

US ophthalmic industry veteran James Mazzo takes the helm of Carl Zeiss Meditec's revamped ophthalmology unit.

Ophthalmology Executive Changes
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
UsernamePublicRestriction

Register